Testing for B-Type Natriuretic Peptide
in the Diagnosis and Assessment of Heart Failure:
What are the Nuances?
Supplement Editor and Roundtable Moderator:
James B. Young, MD
The Cleveland Clinic
Special Issue
June
2004
Supplement
5
to Volume 71
This supplement is supported by an unrestricted educational grant from Biosite Incorporated.
Guidelines for grant-supported supplements to the Cleveland Clinic Journal of Medicine
Education Home | CCF Home | CCJM Home
The
Cleveland Clinic Foundation
Cleveland Clinic Journal of Medicine
9500 Euclid Avenue, NA32
Cleveland, Ohio 44195
216.444.2661, FAX 216.444.9385
ccjm@ccf.org
|
|
|
B-Type natriuretic peptide (BNP) has recently assumed a prominent role in the management of heart failure, owing to its emergence as a therapy in the form of the biologic agent nesiritide and its recognition as a useful diagnostic biomarker for the disease, particularly in the emergency room. The usefulness of BNP as a biomarker in the acute care setting has prompted growing interest in the peptide's potential roles as a diagnostic and prognostic marker in the outpatient setting. To explore these roles, the Cleveland Clinic Journal of Medicine convened a roundtable discussion in March 2004 among a panel consisting of cardiologists with expertise in BNP as well as internists who are now assessing what BNP testing can bring to their practice. The aims were to begin to define the role of BNP testing in the outpatient setting and, in the words of roundtable moderator James Young, MD, "to try to reach consensus about what we know and what we don't know." The transcript of that discussion follows. Tables and figures within the transcript were included by consensus of the panel. |
|
|
|
| CONTENTS | |
|
|
|
|
|
|